Loading organizations...
§ Public · Cambridge, MA, USA
Clinical-stage biopharmaceutical company developing dual-action biologics for solid tumors, including HNSCC.
Bicara Therapeutics has raised $280.0M across 2 funding rounds.
Key people at Bicara Therapeutics.
Bicara Therapeutics has raised $280.0M in total across 2 funding rounds.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing dual-action biologics for the treatment of solid tumors, based in Boston, Massachusetts. The organization focuses on oncology therapeutics, specifically advancing its lead candidate, ficerafusp alfa, to target head and neck squamous cell carcinoma by simultaneously blocking cancer growth signals and disabling immune evasion. Operating as a publicly traded entity on the Nasdaq, the enterprise achieved a valuation exceeding $1 billion following an upsized $362 million initial public offering in September 2024 to fund pivotal clinical trials. Prior to its public market debut, the firm secured a $165 million Series C financing round backed by prominent institutional investors including RA Capital Management, Red Tree Venture Capital, and Omega Funds. Originating as a spin-out from the global biopharmaceutical corporation Biocon, Bicara Therapeutics was founded in 2020 by Claire Mazumdar.
Bicara Therapeutics has raised $280.0M across 2 funding rounds. Most recently, it raised $170.0M Series C in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $170M Series C | Braidwell, Carolyn NG | F Prime Capital, RA Capital, RED Tree Venture Capital, Samsara BioCapital, Third Rock Ventures, Aisling Capital, Deerfield Management, Fairmount | Announced |
| Mar 1, 2023 | $110M Series B | RED Tree Venture Capital, Jake Simson | Baird Capital, F Prime Capital, Samsara BioCapital, Third Rock Ventures, Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, Ketan Patel, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest | Announced |
Bicara Therapeutics has raised $280.0M in total across 2 funding rounds.
Bicara Therapeutics's investors include Braidwell, Carolyn Ng, F-Prime Capital Partners, RA Capital, Red Tree Venture Capital, Samsara BioCapital, Third Rock Ventures, Aisling Capital, Deerfield Management, Fairmount, Jake Simson, Baird Capital.
Key people at Bicara Therapeutics.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors, combining targeted precision with tumor modulation to improve cancer treatment outcomes.[1][2][3] Its lead product, ficerafusp alfa (EGFR x TGF-β), targets PD-L1-positive head and neck squamous cell carcinoma and is in Phase 2/3 trials, while earlier-stage programs like BCA-356 (CAIX x IL-12) address broader neoplasms in preclinical development.[2][4] The company serves cancer patients by tackling unmet needs in solid tumor therapy through innovative biologics like fusion proteins and antibody fusion proteins, demonstrating growth via advancing pipelines and clinical momentum.[1][4]
Bicara Therapeutics emerged as a biotechnology venture focused on bifunctional therapies, with its lead program ficerafusp alfa initiating development around June 2020.[4] While specific founders are not detailed in available sources, the company has built a structured organization with dedicated leadership, board of directors, and investor support, positioning it for clinical advancement.[3] A pivotal moment includes reaching Phase 2/3 for ficerafusp alfa and launching a new program start date of January 28, 2025, reflecting early traction in solid tumor innovation.[4]
Bicara stands out in oncology through its engineering of first-in-class bifunctional biologics that merge tumor-targeting precision (e.g., EGFR antagonists, CAIX inhibitors) with immune-modulating power (e.g., TGF-β, IL-12), enabling dual-action impact on solid tumors.[1][2][4]
Bicara rides the wave of bifunctional antibody therapies in oncology, a trend accelerating due to demands for precise, multi-mechanism treatments amid rising solid tumor prevalence and immunotherapy limitations.[1][2] Timing aligns with maturing Phase 2/3 data for ficerafusp alfa, capitalizing on market forces like advances in protein engineering and regulatory support for tumor-agnostic approaches.[4] By influencing the ecosystem through novel CAIX x IL-12 constructs and pending patents (e.g., BCA202, BCA400), Bicara contributes to next-generation biologics, potentially reshaping head and neck cancer standards.[3][4]
Bicara's trajectory hinges on ficerafusp alfa readout in 2026+, with expansion into IL-12 and other modalities amid booming bispecific/bifunctional demand.[4] Trends like AI-accelerated drug design and combo immunotherapy will propel its pipeline, evolving its role from clinical pioneer to potential market leader in solid tumors. This positions Bicara as a high-momentum biotech, transforming cancer care through dual-action precision.[1][3]
